(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 June 2007 (14.06.2007)

PCT

(10) International Publication Number
WO 2007/067617 A3

(51) International Patent Classification:
A61K 31/397 (2006.01) *A61K 31/519* (2006.01)
A61K 31/445 (2006.01) *A61P 25/18* (2006.01)

(21) International Application Number:
PCT/US2006/046547

(22) International Filing Date:
7 December 2006 (07.12.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/748,434 8 December 2005 (08.12.2005) US

(71) Applicant *(for all designated States except US)*: **AVENTIS PHARMACEUTICALS INC.** [US/US]; 55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BLACK, Mark** [GB/US]; 14 Country Oaks Road, Lebanon, New Jersey 08833 (US). **BOROWSKY, Beth** [US/US]; 11 Crimson King Trail, Flemington, New Jersey 08822 (US). **ROGACKI, Nancy** [US/US]; 921 Clinton Avenue, South Plainfield, New Jersey 07080 (US). **SENYAH, Yaw** [US/US]; 17 Jackson Avenue, Princeton, New Jersey 08540 (US). **STEVENS, Rachel** [US/US]; 62 Brian Street, Lakewood, New Jersey 08701 (US).

(74) Agents: **GUPTA, Balaram** et al.; Sanofi-Aventis U.S. LLC, Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807-0800 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*

(88) Date of publication of the international search report:
1 November 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

(57) Abstract: The present invention discloses and claims a method of treating cognition deficits in a patient suffering from schizophrenia by administering to said patient a therapeutically effective amount of a CB1 receptor antagonist as described herein. In another aspect, this invention also discloses and claims a combination of one or more CB1 receptor antagonists and of one or more antipsychotic agents useful in the treatment of psychiatric disorders . The combination of this invention provides beneficial results in that the combination improves positive and negative symptoms of schizophrenia, while reducing weight gain and catalepsy induced by antipsychotic drugs .

WO 2007/067617 A3